愛美客(300896.SZ)：擬1.90億美元收購韓國REGEN Biotech,Inc.公司控股權 全球化版圖落子再生材料賽道
愛美客(300896.SZ)公佈，公司全資子公司Imeik(HK)Limited(以下簡稱"愛美客香港")與Aisheng Shourui (HK) Limited(以下簡稱"首瑞香港")共同設立Imeik International Limited(以下簡稱"愛美客國際")，擬通過愛美客國際收購註冊地址位於韓國大田市的REGEN Biotech,Inc.公司(以下簡稱"標的公司"、"韓國REGEN Biotech, Inc.")85%的股權，標的公司主要從事醫用材料、醫療器械及醫藥等相關產品的研發、生產與銷售。
愛美客國際擬以現金方式出資，以1.90億美元收購Mount Beacon、 IRC、Mr.Choi持有的韓國REGEN Biotech, Inc.85%的股權。其中愛美客香港出資1.33億美元，首瑞香港出資0.57億美元。
公告稱，此次交易是公司開啓國際化戰略的關鍵舉措，有助於公司進一步夯實在醫美注射填充產品市場的領先優勢，爲公司未來業績的持續增長注入動力。
據悉，標的公司核心產品爲可再生類注射產品，目前該類產品的全球市場增速較快，競品相對較少。標的公司的核心產品已經獲得34個國家和地區的註冊批準，並且建立了廣泛的分銷體系，擁有一定的先發優勢。標的公司產品的主要成分爲PDLLA微球和羧甲基纖維素鈉，產品具有使用方便，安全性高等特點，其有效性已經得到市場的充分認可。標的公司產品AestheFill於2024年1月獲得了中國國家藥品監督管理局(NMPA)證書(國械注進 20243130043)，並於當年實現在中國地區的銷售。
交易完成後，通過整合公司與標的公司雙方的研發、生產和銷售資源，將充分發揮協同效應，有助於公司產品迅速走向國際市場，提升來自國際市場的產品收入；同時，標的公司作爲公司的國際化業務平臺，公司將充分發揮在研發、生產、供應鏈及管理方面的經驗，助力標的公司豐富產品品類、降低生產成本、提高管理效率。
此次交易完成後，公司將標的公司納入公司合併報表範圍，有利於擴大公司資產規模，增強公司未來盈利能力及核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
